Sammenlign metoder

	Flowcytometrianalyse	Caco-2 cellepermeabilitetsanalyse	Populationsfarmakodynamisk modellering
Fagområde	Farmakologi	Farmakologi	Farmakologi
Familie	Process / pipeline	Process / pipeline	Process / pipeline
Oprindelsesår	1976	1989	1992
Ophavsperson	Leonard Herzenberg	Ingrid Hidalgo	Lewis Sheiner and Stephen Roush
Type	cell analysis and sorting	absorption screening	dose-response modeling
Oprindelig kilde	Herzenberg, L. A., Parks, D., Sahaf, B., Perez, O., Roederer, M., & Herzenberg, L. A. (2002). The history and future of the fluorescence-activated cell sorter and flow cytometry: a view from Stanford. Clinical Chemistry, 48(10), 1819-1827.	Hidalgo, I. J., Raub, T. J., & Borchardt, R. T. (1989). Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology, 96(3), 736-749.	Dahlström, B., & Nyberg, L. (1993). Population pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics, 24(1), 45-57.
Aliasser	FACS, fluorescence-activated cell sorting, cell analysis	Caco-2 assay, intestinal permeability, ADME screening	PopPD, population PD, hierarchical PD modeling
Relaterede	3	3	3
Resumé	Flow cytometry is a laser-based technology for analyzing and sorting individual cells based on fluorescent markers. Developed by Leonard Herzenberg in the 1970s, flow cytometry enables rapid assessment of cell phenotype, drug effects on cell populations, and therapeutic cell characterization in immunology and hematology.	The Caco-2 assay is an in vitro model system using human colon carcinoma cell monolayers to screen drug intestinal permeability. Developed by Hidalgo and colleagues in 1989, Caco-2 cells differentiate into an epithelial barrier resembling intestinal mucosa, enabling rapid assessment of drug absorption potential and identification of transporter-mediated transport.	Population pharmacodynamic (PopPD) modeling integrates pharmacokinetics with individual dose-response relationships across patient populations to characterize drug efficacy and tolerability. Pioneered by Lewis Sheiner and colleagues, PopPD accounts for inter-individual variability in drug effects and enables rational dose optimization and response prediction.